Truist has revised its price target for Glaukos (GKOS, Financial), reducing it from $185 to $140 while maintaining a Buy rating on the stock. This adjustment is part of a broader analysis anticipating the first-quarter financial results for the medical technology sector. Despite some uncertainties related to tariffs, the sector is expected to remain attractive to investors, as revenue and earnings appear more stable compared to other sub-sectors.
Analysts at Truist advise that while the current environment remains favorable for the medical technology space, looking ahead to 2025, companies might begin factoring in potential macroeconomic uncertainties. This cautious outlook could influence future financial models and forecasts within the industry.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 13 analysts, the average target price for Glaukos Corp (GKOS, Financial) is $166.69 with a high estimate of $200.00 and a low estimate of $110.00. The average target implies an upside of 85.92% from the current price of $89.66. More detailed estimate data can be found on the Glaukos Corp (GKOS) Forecast page.
Based on the consensus recommendation from 15 brokerage firms, Glaukos Corp's (GKOS, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Glaukos Corp (GKOS, Financial) in one year is $104.96, suggesting a upside of 17.06% from the current price of $89.66. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Glaukos Corp (GKOS) Summary page.
